Evidence map›Paper›PMID 42678911›Full record

ArticleThe American journal of case reports2026

Combination of Multiple-Dose Activated Charcoal and Infusion Therapy That Led to Favorable Outcomes in Colchicine Poisoning: A Case Report.

Manabu Eiraku, Kazuyuki Miyamoto, Keisuke Suzuki, Kazumasa Abe, Tatsuro Tamatsukuri, Asuka Kaizaki-Mitsumoto, Kazuki Kikuchi, Masaharu Yagi, Satoshi Numazawa, Kenji Dohi

Abstract readCase Reports
In one paragraph

Article in The American journal of case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Manabu EirakuDepartment of Emergency, Critical Care and Disaster Medicine, Showa Medical University School of Medicine, Tokyo, Japan.
Kazuyuki MiyamotoDepartment of Emergency, Critical Care and Disaster Medicine, Showa Medical University School of Medicine, Tokyo, Japan.
Keisuke SuzukiDepartment of Emergency, Critical Care and Disaster Medicine, Showa Medical University School of Medicine, Tokyo, Japan.ORCID 0000-0002-2099-1345
Kazumasa AbeDepartment of Hospital Pharmaceutics, Showa Medical University Graduate School of Pharmacy, Tokyo, Japan.
Tatsuro TamatsukuriDepartment of Hospital Pharmaceutics, Showa Medical University Graduate School of Pharmacy, Tokyo, Japan.
Asuka Kaizaki-MitsumotoDepartment of Toxicology, Showa Medical University Graduate School of Pharmacy, Tokyo, Japan.
Kazuki KikuchiDepartment of Emergency, Critical Care and Disaster Medicine, Showa Medical University School of Medicine, Tokyo, Japan.ORCID 0009-0001-2419-1193
Masaharu YagiDepartment of Emergency, Critical Care and Disaster Medicine, Showa Medical University School of Medicine, Tokyo, Japan.ORCID 0009-0000-4525-9225
Satoshi NumazawaDepartment of Toxicology, Showa Medical University Graduate School of Pharmacy, Tokyo, Japan.ORCID 0000-0002-4818-1061
Kenji DohiDepartment of Emergency, Critical Care and Disaster Medicine, Showa Medical University School of Medicine, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND The therapeutic margin of colchicine is narrow, and toxicity occurs easily. No standard treatment exists because its toxicokinetics are poorly understood. Symptoms are usually gastrointestinal, and dehydration occurs easily. Few reports have monitored serum and urinary colchicine levels. CASE REPORT A man in his 20s presented with nausea, vomiting, diarrhea, drowsiness, and dyspnea. He ingested 2 dried Colchicum autumnale bulbs (estimated colchicine: 6.24-15.6 mg) with an energy drink. Activated charcoal with laxative was administered at 27 hours post ingestion (h-PI), followed by multiple-dose activated charcoal (MDAC) every 6 hours (13 doses, 27-101 h-PI), high-volume fluid infusion (Ringer's acetate), and blood purification (hemodialysis [HD] at 48-52 h-PI; hemodiafiltration [HDF] at 71-75 and 98-102 h-PI). Serum colchicine was measured at 16 time points and urine at 11 time points. Serum colchicine at 27 h-PI was 50.3 ng/mL, and was temporally associated with a rapid decrease to 21.2 ng/mL at 35 h-PI, coinciding with initiation of infusion and activated charcoal. A secondary rise to 17.74 ng/mL occurred at 77 h-PI, approximately 2.4 hours after HDF1 completion. Urine colchicine was 110.0 ng/mL at 29 h-PI, then gradually decreased. Serum colchicine changed modestly (12.16 to 5.46 ng/mL) during HD. CONCLUSIONS In this case of severe colchicine poisoning, serial serum and urine concentration monitoring provided a time-resolved profile across concurrent interventions. The observed temporal associations support hypothesis generation regarding the potential roles of renal elimination and MDAC-mediated interruption of enterohepatic recirculation in colchicine clearance, while recognizing that concurrent therapies preclude attribution of effects to any single intervention.

Indexed as

AntidotesCharcoalColchicineHumansMaleAntidotesCharcoalColchicine

Identifiers

PMID42678911
PMCPMC13545977

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.